Blood test may predict chemo failure in aggressive breast cancer
NCT ID NCT04771871
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well standard chemotherapy works in people with triple-negative breast cancer, an aggressive type that lacks targeted treatments. Researchers will also measure tiny molecules called microRNAs and tumor DNA in the blood to see if changes can signal when the drugs stop working. The goal is to find a simple blood test that helps doctors adjust treatment early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin (chemotherapy drugs)
What this could lead to
If successful, this could lead to a simple blood test that tells doctors early when chemotherapy is not working, allowing them to switch treatments sooner.
What could go wrong
This is a small, early-phase study with only 42 people. The blood test idea is still experimental and may not prove reliable enough for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lagos State University Teaching Hospital
NOT_YET_RECRUITINGLagos, Nigeria
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lagos University Teaching Hospital
NOT_YET_RECRUITINGLagos, Nigeria
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Obafemi Awolowo University Teaching Hospital
NOT_YET_RECRUITINGIle-Ife, Oshun, Nigeria
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University College Hospital
RECRUITINGIbadan, Oyo State, 200221, Nigeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••